Market closed
Actinium Pharmaceuticals/$ATNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Ticker
$ATNM
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
31
ISIN
US00507W2061
Website
ATNM Metrics
BasicAdvanced
$46M
-
-$1.47
-0.24
-
Price and volume
Market cap
$46M
Beta
-0.24
52-week high
$10.14
52-week low
$1.03
Average daily volume
342K
Financial strength
Current ratio
9.347
Quick ratio
9.188
Long term debt to equity
3.281
Total debt to equity
5.577
Management effectiveness
Return on assets (TTM)
-39.14%
Return on equity (TTM)
-130.87%
Valuation
Price to book
1.77
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-1.356
Growth
Earnings per share change (TTM)
-13.90%
3-year earnings per share growth (CAGR)
8.83%
What the Analysts think about ATNM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.
ATNM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATNM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATNM News
AllArticlesVideos
Securities Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - Levi & Korsinsky Represents Shareholders
Accesswire·6 hours ago
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM
GlobeNewsWire·7 hours ago
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Actinium Pharmaceuticals, Inc. (ATNM)
Accesswire·9 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals (ATNM) has a market cap of $46M as of May 16, 2025.
What is the P/E ratio for Actinium Pharmaceuticals stock?
The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of May 16, 2025.
Does Actinium Pharmaceuticals stock pay dividends?
No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Actinium Pharmaceuticals dividend payment date?
Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Actinium Pharmaceuticals?
Actinium Pharmaceuticals (ATNM) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.